Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1508794 | 0.84 | PARP1 (0.46) | ALDH1A1L3MBTL1TRPV1MAPTCNR2 | |
| SCHEMBL26615220 | 0.81 | LMNA (0.38) | ALDH1A1LMNAMAPTGRM5KDM4E | |
| SCHEMBL30665359 | 0.81 | LMNA (0.38) | ALDH1A1LMNAMAPTGRM5KDM4E | |
| SCHEMBL768807 | 0.80 | MAPT (0.55) | ALDH1A1LMNAMAPTKDM4EMAOB | |
| SCHEMBL5400102 | 0.79 | DRD1 (0.37) | ALDH1A1LMNAMAPTGRM5KDM4E | |
| SCHEMBL20554131 | 0.78 | MAOB (0.36) | ALDH1A1SCN9ANPSR1GRM5MAOB | |
| SCHEMBL5410275 | 0.77 | MAOB (0.34) | L3MBTL1LMNAMAPTGRM5MAOB | |
| SCHEMBL2315421 | 0.76 | ALDH1A1 (0.40) | ALDH1A1GRM5MAOB | |
| SCHEMBL1508672 | 0.74 | ABCB1 (0.43) | ALDH1A1L3MBTL1SCN9APOLBNPSR1 | |
| SCHEMBL1265527 | 0.74 | CYP19A1 (0.46) | LMNAMAPTGRM5MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8609692-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8604053-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| WO-2013096223-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2352727-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2352726-A1 | TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-08-10 | — | — | EP | disclosed |
| CN-101827585-A | Solid dispersion product containing N-aryl ureido compound | ABBOTT GMBH & CO KG | 2010-09-08 | — | — | CN | disclosed |
| EP-2197426-A2 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | Abbott GmbH & Co. KG (DE) | 2010-06-23 | — | — | EP | disclosed |
| US-20100137360-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010045401-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | disclosed |
| WO-2009050289-A2 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | ABBOTT GMBH & CO. KG (DE) | 2009-04-23 | — | — | WO | disclosed |
| US-20070249578-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-7241757-B2 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2007-07-10 | — | — | US | disclosed |
| US-20040186090-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | US | disclosed |
| US-6750243-B1 | COMPETITIVE INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASES, ESPECIALLY THROMBIN; chemical synthesis; anticoagulants; treatment of thrombosis | AstraZeneća AB (SE) | 2004-06-15 | — | — | US | disclosed |
| EP-1140820-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1140820-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035869-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137360-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV3, TRPV2 | ALDH1A1 1287/4885L3MBTL1 1601/4885TRPV1 1/4885 |
| US-20070249578-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, TFPI | ALDH1A1 4667/4885L3MBTL1 2567/4885TRPV1 3906/4885 |
| US-20040186090-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | ALDH1A1 4181/4885L3MBTL1 1595/4885TRPV1 4489/4885 |
| US-20130158067-A1 | TRPV1 Antagonists | TRPV1, NPY1R, MRGPRX1 | ALDH1A1 2453/4885L3MBTL1 2127/4885TRPV1 1/4885 |
| US-20090143423-A1 | SOLID DISPERSION PRODUCT CONTAINING N-ARYL UREA-BASED COMPOUND | U2SURP, UMPS, HNRNPUL1 | ALDH1A1 1109/4885L3MBTL1 4470/4885TRPV1 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.